These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9853595)

  • 1. European biotechnology firms approve of stock market mergers.
    Michael A
    Nat Biotechnol; 1998 Dec; 16(13):1301. PubMed ID: 9853595
    [No Abstract]   [Full Text] [Related]  

  • 2. The hermit crab solution.
    Silverman E
    Nat Biotechnol; 2006 Mar; 24(3):245-7. PubMed ID: 16680810
    [No Abstract]   [Full Text] [Related]  

  • 3. Commercializing nanotechnology.
    Mazzola L
    Nat Biotechnol; 2003 Oct; 21(10):1137-43. PubMed ID: 14520392
    [No Abstract]   [Full Text] [Related]  

  • 4. Public markets show signs of life.
    Mitchell P
    Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
    [No Abstract]   [Full Text] [Related]  

  • 5. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 6. Will investors return to biotechnology?
    Dorey E
    Nat Biotechnol; 1999 Feb; 17(2):128. PubMed ID: 10052340
    [No Abstract]   [Full Text] [Related]  

  • 7. The rise of venture capital and biotechnology in the US and Europe.
    Lee DP; Dibner MD
    Nat Biotechnol; 2005 Jun; 23(6):672-6. PubMed ID: 15940233
    [No Abstract]   [Full Text] [Related]  

  • 8. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 9. Europe needs a single, deep capital market.
    Hodgson J
    Nat Biotechnol; 2002 Oct; 20(10):960-1. PubMed ID: 12355101
    [No Abstract]   [Full Text] [Related]  

  • 10. White biotechnology: ready to partner and invest in.
    Kircher M
    Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Companies struggle amid stock market gloom.
    Mitchell P
    Nat Biotechnol; 2002 Oct; 20(10):961-2. PubMed ID: 12355102
    [No Abstract]   [Full Text] [Related]  

  • 12. Capital faucet wide-open. Firms' healthcare-related investments up 16% in first half.
    Pallarito K
    Mod Healthc; 1997 Sep; 27(35):76. PubMed ID: 10170390
    [No Abstract]   [Full Text] [Related]  

  • 13. Rainbow biotech--South Africa's emerging sector.
    Louët S
    Nat Biotechnol; 2006 Nov; 24(11):1313-6. PubMed ID: 17093464
    [No Abstract]   [Full Text] [Related]  

  • 14. Could bank loans solve Europe's biotech financing slump?
    Mitchell P
    Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276
    [No Abstract]   [Full Text] [Related]  

  • 15. Australia's bio-regulatory framework: leading the way for stem cell research.
    Hill H
    J Biolaw Bus; 2004; 7(2):61-4. PubMed ID: 15460561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Realizing potential: the state of Asian bioentrepreneurship.
    Tang CM; Mahmud MA; Foo FK; Chu SY; Chiu RI; Tanticharoen M; Zhang L; Chang TW
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE15-22. PubMed ID: 12874972
    [No Abstract]   [Full Text] [Related]  

  • 17. Invention and business performance in the tissue-engineering industry.
    Pangarkar N; Hutmacher DW
    Tissue Eng; 2003 Dec; 9(6):1313-22. PubMed ID: 14670118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enthusiasm cools in Q2.
    Lawrence S
    Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352
    [No Abstract]   [Full Text] [Related]  

  • 20. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.